Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - Vor Bio has reported significant progress in its late-stage clinical programs for telitacicept, a dual BAFF/APRIL inhibitor, demonstrating consistent efficacy and safety across multiple autoimmune diseases [2][3][4] Clinical Developments - Telitacicept has shown promising results in generalized myasthenia gravis (gMG), with 96.2% of patients achieving a ≥ 3-point improvement in MG-ADL after 48 weeks [6] - In Sjögren's disease, telitacicept met primary and secondary endpoints, with 67.1% of patients achieving a modified SRI-4 response at Week 52 compared to 32.7% on placebo [6] - The treatment for systemic lupus erythematosus (SLE) has been reinforced as a potential disease-modifying therapy, with significant reductions in proteinuria and stabilization of kidney function [11][5] Financial Overview - Vor Bio raised expected gross proceeds of $115 million from a public offering in November 2025, which will support operations into the second quarter of 2027 [1][13] - The company reported a net loss of $812.7 million for Q3 2025, primarily due to a loss on change in fair value of outstanding liability-classified warrants [13][15] Leadership and Governance - Vor Bio has expanded its leadership team and board to enhance its global development capabilities, with several key appointments made in 2025 [9][12] Cash Position - As of September 30, 2025, Vor Bio had cash, cash equivalents, and marketable securities totaling $170.5 million, which is expected to fund ongoing operations [13][14]